

Please type a plus sign (+) inside this box 

12-5-1

A

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. ORT-1517

First Inventor KORDIK ET AL.

Title NOVEL AMIDOALKYL-PIPERIDINE AND AMIDOALKYL-PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS

Express Mail Label No. EF195557749US

**APPLICATION ELEMENTS**

See MPEP Chapter 600 concerning utility patent application contents.

- Fee Transmittal Form (e.g., PTO/SB/17)  
*(submit an original and a duplicate for fee processing)*
- Applicant claims small entity status.
- Specification [Total Pages 125]  
*(Preferred arrangement set forth below)*
  - Descriptive Title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings *(if filed)*
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- Drawing(s)/35 USC 113) [Total Sheets ]
- Oath or Declaration [Total Pages 4]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 18 completed)*
    - i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- Application Data Sheet. See 37 CFR 1.76

18.  If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation    Divisional    Continuation-in-Part (CIP) of prior application No.: , filed .

Prior application information: Examiner Group Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Label 000027777 or  Correspondence Address below

Name: Philip S. Johnson, Esq.

Address: Johnson &amp; Johnson

One Johnson &amp; Johnson Plaza

New Brunswick, NJ 08933-7003 USA

## 20. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Mary A. Appollina at:

Telephone: (732) 524-3742 Fax: (732) 524-2808

## 21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Mary A. Appollina	Reg. No. 34087
SIGNATURE	<i>Mary A. Appollina</i>	
DATE	October 22, 2001	

JC952 U.S.  
PTO/22/01JC972 U.S.  
PTO/22/01

10/22/01

<b>FEE TRANSMITTAL</b>	Complete if Known	
	Application Number	
	Filing Date	
	First Named Inventor	KORDIK et al.
	Group Art Unit	
	Examiner Name	
Attorney Docket Number	ORT-1517	

## FEE CALCULATION

### CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$710.00
TOTAL CLAIMS	18 - 20 =	0	x 18.00	\$ 0.00
INDEPENDENT CLAIMS	1 - 3 =	0	x 80.00	\$ 0.00
MULTIPLE DEPENDENT CLAIMS	<input type="checkbox"/>	N/A	\$270.00	
			TOTAL FEES	\$ 710.00

### METHOD OF PAYMENT

- Please charge Deposit Account No. 10-0750/ORT1517/MAA in the amount of \$710.00.  
Three copies of this sheet are enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT1517/MAA. Three copies of this sheet are enclosed.

<b>SUBMITTED BY:</b>		Complete (if applicable)	
Typed or Printed Name	Mary A. Appollina	Reg. No. 34087	
Signature	<i>Mary A. Appollina</i>	Date: 10/22/011	Deposit Account No. 10-0750

DOCKET NO. ORT-1517

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KORDIK ET AL.

For : NOVEL AMIDOALKYL-PIPERIDINE AND AMIDOALKYL-  
PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF  
NERVOUS SYSTEM DISORDERS

Express Mail Certificate

"Express Mail" mailing number: EF195557749US

Date of Deposit: October 22, 2001

I hereby certify that this complete application, including specification pages, claims, Declaration and Power of Attorney, and Assignment, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

KAREN HALL-MORGAN

(Typed or printed name of person mailing paper or fee)

Karen Hall-Morgan  
(Signature of person mailing paper or fee)